NHS opens eight UK clinical trial sites to assess cancer patient response to immunotherapy in partnership with OncoHost


BINYAMINA, Israel, June 16, 2021 /PRNewswire/ — OncoHost, the global leader in host response profiling for improved personalized cancer therapy, today announced a partnership with the United Kingdom National Health Service (NHS), the launch of eight clinical trial sites in the UK. These studies will provide proteomic analysis for patients diagnosed with advanced melanoma or advanced non-small cell lung cancer (NSCLC) receiving immunotherapy to help predict their response to treatment.

The sites will participate and contribute to the ongoing PROPHETIC study, which uses the company’s host response profiling platform, Prophet®.

“Immunotherapy has shown excellent results for various cancers in certain situations, allowing patients to control their cancer for longer with a preserved quality of life and longer survival,” said Dr. David Farrugia, consultant medical oncologist at NHS and principal investigator of all eight NHS clinical trial sites. “However, success with immunotherapy is not guaranteed in every patient, so this PROPHETIC study seeks to identify changes in proteins circulating in the blood, which could help doctors choose the best treatment for each patient. I am delighted that Gloucestershire Oncology Center and its research department have this opportunity to contribute to this growing field of research and I am determined that our center will make a leading national contribution to patient recruitment.”

PROphet® is a unique diagnostic platform that combines proteomic analysis with AI to predict patient response to immunotherapy and identify resistance-related processes, providing clinicians with potential combination strategies to overcome treatment resistance. The platform uses high-throughput protein analysis technology, which scans more than 1,000 proteins in a patient’s plasma, combined with proprietary bioinformatic and machine learning-based algorithms to identify proteomic patterns that are predictive of patient outcome . PROphet® also identifies potential drug targets, furthering the development of new therapeutic strategies. Previous studies conducted in the US and Israel have shown that PROphet® has high accuracy in predicting how patients with NSCLC and melanoma will respond to different therapies.

“In recent years, it has become increasingly clear that immunotherapy is not a one-size-fits-all solution. At OncoHost, we leverage advanced proteomic and AI-based host response science to address the most pressing problem in oncology today – resistance to cancer treatment,” said Dr. Ofer Sharon, CEO of OncoHost. “Our PROPHETIC study provides a more in-depth understanding of patients’ responsiveness to therapy and collaboration with the NHS will give us a great opportunity to expand our research, enhance the capabilities of our technology and increase our knowledge in the field to deliver the ultimate solution for oncologists and physicians.”

This collaboration anticipates the imminent launch of PROphet® later this year. OncoHost continues to open additional clinical trial sites around the world and will expand its research into further cancer indications, including ovarian, head and neck, and genitourinary cancers, with the aim of enabling early identification of non-responsiveness to cancer treatment and discovery new targets to overcome therapy resistance.

About OncoHost

OncoHost combines life sciences research and advanced machine learning technology to develop personalized strategies to maximize the success of cancer therapy. Using proprietary proteomic analysis, the company aims to understand patients’ unique response to therapy and overcome one of the major hurdles in clinical oncology today: resistance to therapy. OncoHost’s Host Response Profiling platform (PROphet®) analyzes proteomic changes in blood samples to monitor the dynamics of biological processes induced by the patient (ie, the host) in response to a particular cancer therapy. This proteomic profile is highly predictive of individual patient outcome, enabling personalized treatment planning. PROphet® also identifies potential drug targets, furthering the development of novel therapeutic strategies and rationally based combination therapies.

For more information visithttp://www.oncohost.com.

Follow OncoHost onLinkedIn, Twitter and Facebook.

OncoHost media contact:
Finn Partners for OncoHost
Lior Feigin
+972 54 282 4503
[email protected]

NHS opens eight UK clinical trial sites to assess cancer patient response to immunotherapy in partnership with OncoHost

Related Links



Leave a Comment